Health, Education & Government
›
Life Sciences & Pharma
›
Cell & Gene Therapy
Patient Identity Tracking
Regulated development and commercialization journeys where clinical, quality, and market access align.
Veeva
Oracle Health Sciences
LabVantage
Medidata
Inside this journey
-
Pre-Discovery
Align the room on outcomes, decision process, and constraints before deeper discovery.
-
Stakeholder Alignment
Confirm decision roles, timelines, regulatory priorities, and what ‘good’ looks like for clinical, courier, manufacturing, and treatment center stakeholders.
Alignment Questions
Quick Context: Where We Are Right Now
- Which title best describes your role on the chain-of-identity project?
- Which therapy type and program phase are you supporting?
- What triggered your evaluation of an identity tracking solution today?
- How many distinct organizations must your chain-of-identity span (clinical collection sites, couriers, manufacturing sites, treatment centers)?
- In one sentence, how would you summarize the single biggest identity-related pain you are trying to solve?
If This Goes Wrong, What Keeps You Up at Night?
- When you picture a confirmed patient-identity mix-up in your program, what is the real, worst-case consequence for patients, data integrity, and the program?
- Have you experienced a near-miss or actual mix-up in the last 24 months? If yes, tell us briefly what happened and how it was discovered.
- How did leadership react the last time an identity event occurred (e.g., immediate audit, policy change, paused recruitment)?
- Which consequences worry you most: regulatory enforcement (FDA), patient harm, trial stoppage, reputational loss, or commercial delay? Select up to two.
- How does the possibility of a mix-up emotionally land with your team—do you sense anxiety, resignation, urgency, or something else?
Who Holds the Keys—and Who's Missing?
- Do you currently have a single accountable owner for chain-of-identity across clinical sites, couriers, manufacturing, and treatment centers, or is it fragmented?
- Please list the core stakeholder groups we should involve (pick all that apply).
- Who needs to sign off on a validation package or acceptance test for a solution like this (titles or teams)?
- Which stakeholder is most likely to resist adding barcode/RFID steps into their workflow, and why?
- How do you typically make cross-functional decisions—single decision-maker, steering committee, or consensus? Please describe the cadence.
Walk Me Through a Day When It Works — and When It Doesn’t
- Which step in your current chain-of-identity workflow do you treat as 'hope it doesn't break'—and why?
- Please map the systems or artifacts used at each major step (e.g., paper labels, spreadsheets, LIMS, EHR, proprietary trackers). List by step.
- How frequently are manual interventions or overrides required during normal operations (e.g., relabeling, manual reconciliation)?
- Do you currently use barcode, RFID, or other auto-identification methods? Select all that apply and note where.
- Tell us about a recent 'near-miss' event in enough detail to understand the root cause and where data or controls were missing.
- Where do you keep chain-of-custody documentation today, and who can access it during an audit?
How Would FDA Judge You Tomorrow?
- If FDA inspected tomorrow, which area of your chain-of-identity documentation would you expect the strongest critique on?
- What specific audit evidence would you need to produce within 24–72 hours to demonstrate traceability from patient to infusion?
- Have you ever received an FDA observation or 483 related to identity, chain-of-custody, or data integrity? If yes, summarize the finding and corrective action.
- What failure-mode tolerances would your QA team accept before stopping shipments or pausing enrollments (e.g., allowable % of reconciliation errors)?
- Which regulators or country-specific requirements beyond FDA affect your chain-of-identity needs?
What Would 'Safe' Look Like — In Measurable Terms?
- If you could set three non-negotiable metrics for identity reliability, what would they be (e.g., 0 mix-ups, 99.99% scan success, time-to-traceability <1 hour)?
- Which of these success signals matter most for your internal stakeholders? Select up to three.
- What target percent scan accuracy or identifier match rate would satisfy your QA team?
- How fast must you be able to produce end-to-end traceability reporting for an FDA request?
- What would constitute an unacceptable residual risk level after implementing a new identity system?
Integration, Hardware, and Sterile Challenges
- Which is the riskiest technical dependency for your program: hardware in sterile environments, LIMS/EHR integrations, or courier data handoffs?
- Which LIMS, EHR, or clinical systems must the solution integrate with? List vendor names and whether API/HL7/FHIR access is available.
- Do you have technical resources and credentials ready for integration work (e.g., test environment access, API keys, SFTP), or will that be a blocker?
- Which hardware constraints apply at your clinical sites or manufacturing floors (e.g., sterile-field scanning, disposable devices only, decontamination requirements)?
- Have you validated wireless/network connectivity in all sites (including couriers' vehicles / drop-off points) or do you expect offline-first behavior to be required?
- What are your expectations for vendor-provided hardware support and spare provisioning during deployment?
People, Training, and Change—Who Will Actually Use It?
- How willing are frontline staff to add scanning steps when they perceive it may lengthen patient interactions?
- Who would be the day-to-day system champions at clinical sites, couriers, manufacturing, and treatment centers (name roles/titles)?
- What is your current staff turnover rate for the teams who will use the system (approx.), and how does that affect training plans?
- What training formats have historically driven the best adoption at your sites (in-person, train-the-trainer, e-learning, quick reference cards)? Select all that apply.
- How will you measure frontline compliance to scanning and chain-of-custody steps during a pilot?
- What cultural or operational objections do you anticipate from sites or couriers, and how have you addressed similar resistance in the past?
Decision, Budget, and Timeline—What Will Make You Say Yes?
- What is the primary decision criterion for approving a full deployment (risk reduction, regulatory readiness, cost, time-to-live, or something else)?
- What is your target timeline from pilot start to full production across initial sites?
- Who controls the budget for this purchase and what procurement steps are required (RFP, security review, legal agreements)?
- What contractual or data-security requirements are absolute deal-breakers (e.g., data residency, SOC2, business associate agreement)?
- What would be the minimum pilot scope (sites/patients) and duration that would convince leadership to proceed?
- Are there governance or steering committees that must approve milestones? If yes, what cadence and members?
Next Steps and Evidence Needed to Move Forward
- What would you need to see in a POC/pilot to move straight to Mutual Commit—specific deliverables, metrics, or artifacts?
- Which pilot success criteria are absolute must-haves versus nice-to-haves? Please list must-haves first.
- How much internal resource (FTEs or hours) can you commit to a pilot on a weekly basis?
- Who are the three people we should engage immediately to scope a pilot (name and role)?
- What are the top three risks that, if unaddressed in a pilot, would stop you from proceeding to full deployment?
- If we delivered a tailored pilot plan today, how soon could you start?
-
Current State Mapping
Document existing chain-of-identity workflows, recent near-miss events, data sources, and integration points with LIMS/EHR systems.
Current State
Starting Line: Tell Us How You Really Track Identity Today
- Walk me through the exact steps you use from patient enrollment to infusion for assigning and verifying patient identifiers—who does what, in what order?
- Which of the following tools are actively used in those steps today?
- How often do those workflows run at a given site or cohort (e.g., number of collections / infusions per week)?
- What physical artifacts do you rely on to prove chain-of-identity (labels, wristbands, manifest PDFs, courier receipts, logbooks)?
- Who in your organization is nominally responsible for maintaining the canonical patient identifier (role/title)?
Where Are Things Actually Breaking — Even If You’ve Learned to Ignore It
- When was the last time you had a near-miss or identity uncertainty event, and what actually happened?
- How frequently do you experience near-misses or identity anomalies across your sites?
- Which immediate causes tend to trigger those events?
- When a near-miss occurs, how quickly can you trace the item back to a single source (minutes/hours/days/never)?
- Describe the real-world impact of your most concerning near-miss—clinical delay, reconsent, lost batch, or inspection finding?
Who Holds the Real Authority — And Who's Quietly Blocking Progress?
- If you had to name one person or team whose buy-in would determine whether identity controls succeed, who would that be and why?
- Across clinical sites, couriers, manufacturing, and treatment centers: who is accountable, who is consulted, and who simply executes in practice?
- How do frontline staff usually respond when asked to add a scanning or verification step—enthusiastic, compliant with friction, or resistant? Give a recent example.
- How stable are the people in those roles (turnover, contractors, seasonal staff), and how does that affect identity reliability?
- Who will need to sign off on changes to identity workflows (titles/roles)?
What Are We Blind To — Where the Paper Trail and Systems Don’t Align
- Which systems currently carry patient or sample identifiers that should be reconciled (list LIMS, EHR, courier portals, spreadsheets)?
- Do those systems have live integration points today (APIs, HL7, flat-file drops, manual exports)?
- How consistent are the identifier formats across systems (same ID, different prefixes, local numbering, or no standard)?
- Which physical hardware is used for identification at each step (scanner models, printers, RFID readers), and are any required to operate in sterile environments?
- Who owns integrations and data mappings today (IT, LIMS vendor, external integrator, or site)?
If an Inspector Asked For Your Chain-of-Identity Right Now, Could You Deliver It?
- Have you had FDA or other regulatory inspections that raised questions about traceability or identity in the last 3 years? If yes, what was cited?
- What documentation do you currently assemble for an audit to prove end-to-end identity (electronic logs, printouts, chain-of-custody PDFs, validation reports)?
- What would an FDA-critical acceptance criterion look like for you (traceability to patient within X minutes, 100% scan completion, audit trail immutable for Y years)?
- If a chain-of-identity failure forced you to halt a program, what would the operational and commercial consequences be (time to resume, patient impact, financial exposure)?
What Would Zero Mix-Ups Actually Look Like for Your Team?
- In an ideal world, what measurable KPIs would tell you identity is solved (e.g., scan rate, reconciliation time, near-miss rate)?
- What is your target identity reliability percentage and your acceptable failure-mode tolerance for clinical/regulatory purposes?
- Which stakeholders would need to feel differently (clinicians, couriers, QA, manufacturing) for this to be considered successful, and how would you measure their confidence?
- What reporting or dashboard views would reduce your day-to-day worry about identity (real-time exceptions, per-site heatmaps, executive summaries)?
What Would It Really Take to Get There — Constraints, Resources, and The Non-Negotiables
- Which of the following validation and qualification approaches do you require or prefer for new identity systems?
- What integration timeline constraints do you have (must be live before next cohort, within 3 months, within 6 months, or flexible)?
- What budget holder or procurement approval is required to move forward (title/department), and is funding already allocated?
- What are your non-negotiable constraints (hardware allowed in sterile area, vendor-approved components, data residency requirements, minimum uptime)?
- Who will own day-to-day validation and post-deployment governance if we partner (roles and an internal point of contact)?
Quick Wins and Pilot Thinking — What Can We Do This Quarter?
- What single, small change could reduce your near-miss risk immediately (e.g., mandatory scan at collection, courier scan at pick-up, standardize label format)?
- Which site or workflow would be the best pilot for a proof-of-concept to validate end-to-end chain-of-identity?
- How would you measure pilot success (specific acceptance tests, KPIs, and stakeholder approvals)?
- What barriers do you foresee to running a pilot quickly (access to sterile spaces, IT windows, courier coordination, data sharing agreements)?
- If we proposed a short discovery workshop to map your end-to-end flow with stakeholders, who should attend and what date windows work in the next 30–60 days?
-
-
Outcome Discovery
Define target identity reliability, audit acceptance criteria, failure-mode tolerances, and measurable success signals for FDA readiness.
Discovery Questions
Quick Check — Where Do You Want to Land on FDA Readiness?
- In one sentence, how would you describe your current confidence level in being audit-ready for chain-of-identity?
- Who in your organization is the single point person responsible for declaring ‘FDA-ready’ for identity traceability?
- Which stakeholder groups must sign off before you consider identity controls acceptable (select all that apply)?
- Roughly when would you need audit-ready evidence in hand to avoid program impact (month/quarter)?
- What current artifacts do you already have that directly demonstrate chain-of-identity (e.g., scanned labels, LIMS audit logs, signed chain-of-custody)?
If the FDA Showed Up Tomorrow, Could You Prove It?
- If an FDA inspector asked for end-to-end proof that a patient’s apheresis bag through infusion stayed matched, could you produce it within five business days?
- Which artifacts would you present first to prove identity continuity (choose up to three)?
- Tell us about the last time you couldn’t answer an auditor’s question on identity—what specifically couldn’t you show, and how long did it take to investigate?
- What internal phrases or euphemisms do stakeholders use when they mean ‘we’re a little shaky on traceability’?
- How would you describe the single biggest embarrassment or regulatory exposure you fear around identity errors?
How Many Ways Can Identity Break Before It’s Catastrophic?
- Which failure modes keep you awake at night—the ones you assume could happen but aren’t sure you can prove detection for?
- How often have you had a near-miss related to chain-of-identity in the last 12 months?
- When a near-miss occurred, how long did it take from discovery to root-cause identification and containment?
- What detection methods currently catch these failures (manual checks, barcode scans, visual verification, automated alerts)?
- If an identity mismatch occurred and reached a patient, what are the immediate business and regulatory consequences you anticipate?
What Would ‘Reasonable Assurance’ Actually Look Like?
- If you had to pick one numeric target for identity reliability that would make leadership comfortable, what would it be (e.g., 99.9% of scans matched end-to-end)?
- Beyond a percentage, what operational conditions must be met for you to declare success (detection latency, audit completion time, retention period)?
- What tolerance do you have for undetected errors during a pilot phase versus full production (zero tolerance vs limited sentinel sampling)?
- Who must be convinced by the numbers—whose approval will hinge on meeting these reliability targets?
- What would you accept as evidence that a failure was contained and will not recur (root-cause report, corrective action, updated SOPs, retesting)?
What Evidence Will Make the FDA Sleep Easier?
- Which document types do you believe are mandatory for FDA acceptance of chain-of-identity (pick all that you think apply)?
- Has the FDA previously highlighted a specific gap in your identity documentation? If yes, what was it and how was it documented?
- How do you currently package evidence for external reviewers—single PDF packet, segmented system exports, or ad-hoc emails and screenshots?
- Who owns the truth-of-record for identity artifacts across the workflow (clinical site, courier, manufacturer, or treatment center)?
- If we were to generate an FDA-ready audit packet for one patient, what must it include to pass your internal review?
Where Do Trade-offs Hide—and Who Gets Blamed?
- What operational trade-offs are you currently making between speed, sterility, and identity verification that keep you uneasy?
- If a hardware scan adds 30 seconds to a bedside workflow, who raises the most resistance and how do they usually push back?
- When cross-organizational issues occur (site vs courier vs manufacturing), what is your escalation path and who ultimately owns the resolution?
- What non-technical barriers have stalled past identity projects (budget, vendor fatigue, change management, procurement)?
- How do you prefer responsibility and liability to be laid out in acceptance criteria (clear owner per artifact, joint sign-off, or vendor-assumed validation)?
Signals of Success — What Will Tell Us We Nailed It?
- Which KPIs would you watch daily or weekly to know the solution is working (pick up to four)?
- What absolute thresholds on those KPIs would make you comfortable signing off on FDA readiness?
- Beyond numbers, what qualitative feedback from clinical or manufacturing staff would convince you the process is sustainable?
- Who will be the formal acceptance authority for pilot success, and what form of sign-off do they require (email, documented QA approval, governance meeting)?
- How long after go-live would you want to monitor KPIs before moving to full-scale roll-out?
Start Small, Prove Big — What Must Be True in the Pilot?
- If we run a pilot at one clinical site and one manufacturing line, what minimum acceptance criteria must pass to authorize scale?
- Which integrations are must-haves for the pilot (select all that apply)?
- What sample size (number of patients or batches) do you consider statistically meaningful for a pilot validation?
- What failure-mode testing do you want included in the pilot (simulated mislabel, missed scan, connectivity loss, courier misroute)?
- Who must be trained and certified before the pilot starts, and how will competency be demonstrated?
If the Timeline Slips — What’s the Real Cost?
- If you miss the desired FDA-ready date by three months, what downstream impacts do you expect (trial hold, delayed submissions, reputational damage)?
- Which of those impacts worries you most from a program-survival perspective?
- What internal contingency plans do you have if audit evidence is incomplete when required (pause enrollments, add manual reconciliation, ad-hoc CAPA)?
- Who needs to be informed first if we discover a material gap during validation that affects go/no-go timing?
- What level of transparency with the FDA are you comfortable with if a gap is found prior to inspection?
Decision Confidence — What Will Make Your Leadership Say Yes?
- What are the top three questions leadership will ask before approving a go-live for identity controls?
- Which artifacts or demonstrations would shorten the approval cycle the most (live demo, audit packet sample, third-party validation)?
- What budget or procurement milestones must be achieved before you can commit to a full deployment?
- If we commit to a pilot now, what would make you change your mind before completion (emerging risk, vendor performance, internal re-prioritization)?
- Finally, what is one non-negotiable outcome you must see from Outcome Discovery to recommend moving forward?
-
Solution Experience
Validate how the platform delivers end-to-end chain-of-identity using the customer’s real workflows and failure scenarios.
Experience Meetings
- Experience Pre-Check & Data Handoff
- End-to-End Workflow Walkthrough (Live)
- Failure-Mode Simulation & Recovery Exercises (Hands-on)
- Acceptance Criteria & FDA Readiness Review
- Pilot Execution Planning & Governance
- Reach a documented go/no-go decision for the pilot phase.
- Seller: Publish the evidence-capture checklist for each simulation scenario.
- Simulation Ground Rules & Objectives
- Prove the platform detects and prevents each prioritized failure within the pre-agreed tolerances.
- Capture complete, audit-ready evidence packs for every scenario executed.
- Confirm the customer's explicit validation that the platform behavior mitigates the stated consequences.
- Create a prioritized remediation list with owners and target dates for any failures to be fixed.
- Seller: Produce scenario result packs (logs, screenshots, timestamps) for each executed scenario.
- Customer: Review and sign off on pass/fail status for each scenario or provide detailed objections.
- Seller: Triage and commit timelines for high-priority defects found during simulations.
- Customer & Seller: Update SOPs/runbooks to reflect validated recovery steps.
- Review Measured Results vs Success Signals
- Obtain an explicit mapping of simulation evidence to each FDA/audit acceptance criterion.
- Agree remediation items with owners and timelines sufficient to remediate high-risk gaps.
- Secure sign-off authority and define required validation documentation for inspection readiness.
- Introductions & Objectives
- Seller: Deliver a formal validation report mapping evidence to acceptance criteria.
- Customer: Confirm required signatories for validation sign-off and provide timelines.
- Seller & Customer: Publish remediation tracker with owners, actions, and target completion dates.
- Customer: Decide and communicate go/no-go for pilot initiation.
- Pilot Objectives and Success Metrics
- Finalize a signed pilot plan with dates, sites, patient/batch counts, and owners.
- Confirm hardware, sterile-environment access, and training readiness for pilot start.
- Agree on monitoring dashboards and escalation procedures to manage pilot risks in real time.
- Define the post-pilot review, metrics to be delivered, and sign-off process.
- Customer: Approve and sign the pilot plan and confirm site readiness dates.
- Seller: Deliver training schedule, runbooks, and monitoring dashboard access.
- Seller & Customer: Provision and ship scanning hardware to sites and confirm sterile-field installation plans.
- Seller: Stand up pilot incident response team and publish escalation contacts.
- Obtain a single-sentence current-state diagnosis that all parties accept.
- Document concrete consequence metrics (time, cost, regulatory risk) tied to the current state.
- Agree a single-sentence future-state outcome to prove during the experience.
- Secure all data artifacts, credentials, and nominated participants with delivery dates.
- Finalize the list of real workflows and failure scenarios to validate.
- Customer: Provide LIMS/EHR sample export, SOPs, label templates, and near-miss reports by agreed date.
- Seller: Provision test environment and confirm access details.
- Customer: Nominate participants (quality, manufacturing, clinical, courier) for simulations.
- Seller: Draft and share final scenario runbook and checklist prior to live sessions.
- Recap Objectives & Success Signals
- Demonstrate a mapped, stepwise flow from enrollment to infusion that ties platform actions to the customer's future-state outcome.
- Identify and document all integration field mismatches and hardware constraints that would prevent full proof of the future state.
- Agree the exact evidence and logs that will be captured during failure-mode simulations for audit purposes.
- Assign owners for each integration and hardware remediation task.
- Seller: Configure missing field mappings and prepare a test data load for the simulations.
- Customer: Provide credentials and endpoint details for sandbox LIMS/EHR interfaces.
- Customer: Make available required scanning hardware or confirm procurement timelines.
- Map Results to FDA Acceptance Criteria
- Scope, Sites, and Patient/Batch Count
- Live Enrollment to Collection Walkthrough
- Current State: One-Sentence Confirmation
- Scenario A: Label Mismatch / Near-Miss Detection
- Residual Risk & Tolerance Discussion
- Consequence Quantification
- Scenario B: Courier Chain Break / Delayed Custody
- Courier Handoff & Chain-of-Custody Demonstration
- Schedule, Resource & Hardware Plan
- Future State Outcome Definition
- Training & Runbook Distribution
- Manufacturing & Release Mapping
- Remediation Plan, Owners & Timelines
-
Solution Scope
Define included modules, hardware, integrations (LIMS/EHR), responsibilities, validation steps, and acceptance tests.
Scope Configuration
- Assign and Manage Unique Patient Identifiers
- Install Barcode Scanners and RFID Readers
- Configure LIMS and EHR Integration Connectors
- Deploy Mobile Scanning Stations for Clinical Sites
- Implement Electronic Chain-of-Custody Logs
- Migrate Legacy Tracking Records to Platform
- Run Proof-of-Concept Scanning Pilot
- Deploy Sterile-Compatible Scanner Housings
- Generate Audit-Ready Product Release Documentation
- Implement Role-Based Access and Electronic Signatures
- Install On-Premise or Cloud Tracking Server
- Provide Onsite Staff Training and SOP Coaching
- Integrate Courier Tracking Events into Chain-of-Identity
- Set Up Real-Time Chain-of-Identity Alerts
Scope Questions
Assign and Manage Unique Patient Identifiers
- Do you currently assign a unique patient identifier (UPI) at enrollment?
- If you already have UPIs, what format do they use (e.g., alphanumeric, GUID, site-prefixed)?
- Do UPIs need to be synchronized across multiple organizations (clinical sites, couriers, manufacturing, treatment centers)?
- Are there regulatory or audit constraints on the UPI structure (e.g., de-identification, patient PHI separation)?
- Which systems must consume or report the UPI (select all that apply)?
- Describe any existing mapping rules or logic we must preserve when implementing new UPIs (e.g., legacy ID → new ID mapping).
Install Barcode Scanners and RFID Readers
- Which sites will require scanners/readers (clinical sites, courier depots, manufacturing, treatment centers)?
- Which scanning technologies do you prefer or require?
- Estimate the number of scanning devices needed per site type (provide numeric ranges or counts).
- Do devices need to operate in sterile/cleanroom environments or pass decontamination protocols?
- What connectivity is available at each site for scanners (Wi-Fi, wired LAN, cellular, offline mode required)?
- Do you require vendor-preferred models, existing procurement contracts, or on-site IT approval for hardware?
Configure LIMS and EHR Integration Connectors
- Which LIMS or EHR systems need connectors (list vendor names and versions)?
- What integration pattern is required for each system?
- Are there existing integration middleware or an integration team we must coordinate with?
- What data elements must be exchanged (e.g., patient ID, sample ID, custody events, timestamps)?
- Are there security or network constraints (VPN, IP allowlist, client certs) that will affect connector deployment?
- What are your expected SLAs for integration latency and error handling?
Deploy Mobile Scanning Stations for Clinical Sites
- Do clinical sites require portable/mobile scanning stations versus fixed readers?
- What environmental or power constraints exist at clinical sites (battery-only, limited outlets, small spaces)?
- Will mobile stations be used inside sterile rooms or patient areas where additional cleaning/disinfection is required?
- How many shifts/users per day will rely on mobile stations at each site?
- Do you require mounting, charging docks, or transport cases as part of the mobile station deliverable?
- Describe expected workflows the mobile station must support (e.g., enrollment scan → collection scan → handoff to courier).
Implement Electronic Chain-of-Custody Logs
- Which custody events must be captured electronically (collection, handoff, receipt, processing, release, infusion)?
- Do you require timestamped signatures or attestation for custody events?
- Should custody logs be auditable and exportable in a particular format (e.g., CSV, PDF audit-pack)?
- Are there required retention policies or archiving requirements for chain-of-custody records?
- Will custody events sometimes occur offline and need later reconciliation?
- Who is the primary approver(s) for custody records during validation and release (role names)?
Migrate Legacy Tracking Records to Platform
- What legacy data sources must be migrated (spreadsheets, legacy LIMS, physical logs)?
- Estimate the volume of legacy records to migrate (number of records or time range).
- Are there data quality issues expected (duplicates, missing timestamps, inconsistent IDs) that require transformation?
- Do legacy records require mapping to new identifiers or to new custody event taxonomy?
- Are there regulatory considerations for migrating historical records (audit trails, chain-of-custody continuity)?
- Would you like a sample migration and reconciliation report before full migration?
Run Proof-of-Concept Scanning Pilot
- Which single workflow or site should be used for the pilot (e.g., one clinical site, one courier route, one manufacturing line)?
- What success criteria do you require for the POC (scan accuracy %, uptime, integration reliability)?
- How long should the POC run to collect representative data (days/weeks/batches)?
- Which stakeholder groups must approve pilot results (QA, manufacturing, clinical ops, courier ops)?
- Do you require simulated failure scenarios to be tested during the POC (mis-scans, label damage, offline operations)?
- Will pilot data be used to generate validation artifacts for audit (logs, test scripts, deviation records)?
Deploy Sterile-Compatible Scanner Housings
- Do you require specially certified sterile-compatible housings for scanners?
- What sterilization protocols must housings withstand (autoclave, VHP, wipe-down with IPA)?
- Will housings be single-use, reusable, or mixed?
- Do housings require any special mounting or hands-free operation for sterile workflows?
- Are there material compatibility requirements (medical-grade plastics, biocompatible materials)?
- Do you require qualification/installation IQ/OQ documentation for the housings?
Generate Audit-Ready Product Release Documentation
- What release artifacts are required by your QA/regulatory team (release certificate, chain-of-identity pack, batch record)?
- Do documents need to be electronically signed and tamper-evident for FDA audits?
- What format and retention policy do you require for audit packs (PDF/A, CSV extracts, secure archive duration)?
- Which stakeholders should be included in sign-off workflows for release documentation?
- Do you require automated generation of audit packs on each release or on-demand generation only?
- Are there specific validators or acceptance criteria that must be embedded in the release report (e.g., chain continuity checks)?
Implement Role-Based Access and Electronic Signatures
- How many distinct user roles do you anticipate (e.g., site tech, courier, production operator, QA reviewer) and approximate counts per role?
- Do specific roles require restricted access to PHI or critical actions (e.g., release approvals)?
- Are electronic signatures required to meet 21 CFR Part 11 expectations for some actions?
- Do you require single sign-on (SSO) integration and which identity provider(s) do you use?
- Do you need configurable audit logging per role and periodic access reviews?
- Would you like role templates (clinical, courier, manufacturing, QA) pre-configured?
-
Mutual Commit
Finalize commercial and legal terms, lock timelines, acceptance criteria, and governance for regulatory readiness.
Agreement Modules
- Statement of Work (SOW)
- Master Services Agreement (MSA)
- Order Form / Commercial Terms
- Data Processing & Privacy Agreement (DPA)
- Regulatory Readiness Annex
- Validation & Acceptance Test Plan (IQ/OQ/PQ)
- Service Level Agreement (SLA) & Support
- Hardware Supply & Installation Agreement
- Integration & IT Access Agreement
- Training & Change Management Plan
- Site Access & Logistics Agreement
- Change Order & Scope Management
- Governance, Roles & Escalation Plan
- Acceptance Sign-off & Closeout Certificate
- Confidentiality Agreement (NDA) — if not already executed
-
Deployment
Operationalize rollout with readiness checks, enablement, and outcome validation.
-
Pre-Deployment Readiness
Confirm data migration, hardware access in sterile environments, integration credentials, and staff training plans are in place.
Readiness Questions
Quick temperature check — Where are you today?
- Give a short summary of your current deployment timeline, the primary program owner, and the single biggest constraint right now.
- What is your target go-live window for the first production patient?
- How many clinical, manufacturing, and treatment sites are in scope for the initial deployment?
- Who are the core decision-makers we should engage? Select all that apply.
- Has a near-miss, audit finding, or inspection gap recently triggered this program?
- If yes or unsure, briefly describe the incident, what failed, and the downstream regulatory impact or actions taken.
If a single data migration mistake could stop your trial, are you truly ready?
- If a single data-migration error could create an irrecoverable mix-up, how confident are you in the completeness and cleanliness of your legacy identifier data?
- Which systems currently hold the patient identifiers and chain-of-custody records we must migrate or reconcile? Select all that apply.
- Estimate what percentage of your historical patient/lot records are already machine-readable (barcodes/RFID) versus handwritten or free-text.
- Are there identifiers that cannot be exported or linked due to privacy, contractual, or technical restrictions?
- Who will own data reconciliation during migration and how many full-time equivalents (FTEs) can you allocate to that work?
- Describe any known data quality problems (duplicate IDs, missing timestamps, mismatched site codes) and how frequently they occur.
Sterile rooms, scanners, and the moment of truth
- When we introduce scanners into your controlled/sterile fields, what usually breaks first—permissions, physical access, or human habit?
- Which types of scanning hardware are permitted today in your controlled environments? Select all that apply.
- Do you require specific sterilization certification, housings, or cleanroom qualifications for devices we intend to install?
- How are sterile-area access policies and device placement approvals handled today, and who signs off?
- Will hardware installation trigger environmental validation (particle counts, mapping) or requalification steps at the site?
What if the systems stop talking?
- If our integration calls began failing during a batch release window, how quickly could your organization detect and remediate that without disrupting patient care?
- Which target systems must we integrate with for go-live? Select all that apply.
- What authentication and transfer methods are supported or preferred for integrations?
- Do you have API documentation, sandbox/test environments, and credentials available for integration work?
- Who will be our day-to-day integration contact in IT and what is their expected SLA for providing test credentials and troubleshooting?
- What change-window restrictions or maintenance windows must we observe for integration work?
The people problem — who will actually scan?
- How many staff would prefer to 'write it down' rather than stop and scan because scanning feels like a risk to patient throughput?
- Provide estimated counts of frontline users requiring training in the first 90 days by role (e.g., clinical nurses, manufacturing techs, couriers, QA reviewers).
- What shift patterns, language needs, or credentialing constraints will affect how we schedule and deliver training?
- Have you identified super-users, validators, and trainers who will support go-live and ongoing adoption?
- How will we measure and record successful completion of training and competency?
- What friction points or objections have users raised when new scanning steps were introduced previously?
What would make the pilot fail even if the tech works?
- Assuming the technology performs perfectly, what political, commercial, or procedural reasons could still cause you to halt the pilot?
- Which acceptance criteria are non-negotiable for you to move from pilot to production? Select all that apply.
- How many successful end-to-end patients or batches do you require to accept the pilot?
- Who must sign pilot acceptance and what format must their sign-off take (e.g., formal QA memo, cross-functional committee approval)?
- Which monitoring metrics must we capture during the pilot (examples: scan success rate, time-per-step, manual overrides)? Select all that apply.
Regulators and nightmares — are you audit-ready?
- If FDA inspected tomorrow and asked for chain-of-identity for a random patient, could you deliver a full audit trail within one hour?
- Do you currently maintain audit-ready chain-of-identity documentation for recent patients as part of your standard operating procedures?
- Which regulatory standards or inspection expectations should we prioritize for documentation and validation?
- Do you have historical audit findings related to identity, chain-of-custody, or labeling we should be aware of?
- What contingency steps will you expect if a traceability gap is discovered post-deployment (quarantine, root-cause, patient notification)? Select all that apply.
- Who is the escalation owner for regulatory communications, and what is their expected response SLA in case of traceability incidents?
-
Deployment Enablement
Schedule installations, coordinate multi-site teams and couriers, run pilot batches, and execute staff enablement with clear owners.
-
Validation Checklist
Run acceptance tests, capture audit-ready chain-of-identity documentation, and confirm traceability across clinical-to-infusion workflows.
Validation Questions
Start Here: Tell Us About Your Program
- What is your role and primary responsibility in the cell therapy program?
- Which therapies or trial phases are you responsible for right now?
- How many active sites, couriers, and manufacturing locations are in your current chain-of-identity footprint?
- What systems are currently used to track identity and custody in your workflows?
- Briefly describe how a patient’s identifier is created and travels from enrollment to infusion in your current process.
What’s Keeping You Up at Night About Identity?
- If a single identity mix-up could pause your program, what would that do to your timelines, inspections, and team morale?
- How recently have you experienced a near-miss or documented identity discrepancy?
- When those near-misses happened, what was the immediate operational impact (e.g., patient delays, batch holds, regulatory notification)?
- How does the potential of an identity error make you or your team feel when preparing for inspections or patient treatments?
- Who outside your organization gets most anxious about identity risk (e.g., investigators, couriers, manufacturing QA, hospital partners)?
Where the Chain Actually Breaks (Tell the Stories)
- What’s one specific moment in your workflow where you’d bet the identity risk is highest—and why do you think that is?
- Walk me through the last time a mismatch or near-miss was discovered—how was it found, who discovered it, and what immediate steps followed?
- Which handoffs are most manual today (paper labels, verbal confirmation, manual entries)?
- How often do sterile-environment constraints (gloves, hood access, limited hardware) force workarounds that compromise scanning or labeling?
- Which data or documents are hardest to reconcile during an investigation (chain-of-custody logs, timestamp gaps, scanned images, LIMS records)?
If the FDA Walked In Tomorrow, What Would They Demand?
- Imagine an inspection tomorrow—what gaps in your chain-of-identity documentation would you be most worried the inspector would flag?
- What are your internal audit acceptance criteria today for identity integrity and traceability?
- How would an FDA observation around identity affect your approval timelines or ongoing trials financially and operationally?
- Which regulatory documents or standards are you trying hardest to satisfy right now (e.g., 21 CFR Part 11 evidence, validation protocols, audit trails)?
- If you could show one single piece of evidence to an inspector to demonstrate identity integrity, what would you want it to be?
What Would Perfect Identity Reliability Actually Feel Like?
- If identity reliability were solved, what day-to-day stress or tasks would disappear for you and your team?
- Which measurable signals would convince you we’d achieved that reliability (e.g., 0 identity events, reconciliation time reduced by X, audit pass rate)?
- What maximum tolerances for failure are acceptable to you (e.g., allowable mismatch investigations per X patients)?
- How would clinicians and patients need to experience the system so it doesn’t add friction to care (speed, simplicity, clear fallbacks)?
- What would a successful first pilot look and feel like to your QA and inspection teams?
People, Process, and Tech: Who Holds the Thread?
- Who are the critical stakeholders we need to involve to make identity changes stick (names or roles)?
- Where do decision bottlenecks live today—procurement, IT security, clinical leadership, or elsewhere?
- How do you prefer to handle governance for identity changes—centralized program team, site-by-site rollouts, or a federated model?
- What training cadence and format work best for your staff in sterile and clinical environments?
- Which parties will need legal or contractual commitments around custody and data sharing?
Deployment Realities We Can’t Ignore
- What hardware and environmental constraints exist at your sites that could block barcode/RFID adoption (sterility, limited power, space, PPE)?
- How mature are your integration points with LIMS/EHR—are there APIs, batch exports, or manual rekeying today?
- What are your biggest concerns about data migration from legacy logs into an electronic chain-of-identity?
- If we needed to run pilot batches, what constraints would limit the number or timing of those pilots?
- What acceptance tests would your QA team insist on before sign-off (list concrete tests or metrics)?
Decisions, Timelines, and Deal Breakers
- What is your desired timeline from pilot to full production for an identity solution?
- What internal approvals or procurement milestones must happen before you can proceed?
- Are there absolute deal breakers we should know about (e.g., cannot install devices in certain zones, no cloud hosting, specific vendor restrictions)?
- What level of price certainty vs. scope flexibility do you need to approve a purchase?
- Who will sign the final commercial and legal terms on your side and what information do they need to feel comfortable?
How We’ll Measure Success Together
- Which KPIs will you use to evaluate whether an identity solution succeeded (pick up to three)?
- What cadence of reporting and evidence (dashboards, audit packs, executive reviews) keeps you confident post-deployment?
- If we achieved your top three KPIs within six months, what would you want documented as the formal success signoff?
- What lingering risks would you still want us to monitor after go-live?
- What would make you recommend this identity solution to peers in other programs or organizations?
-
-
Success
Review outcomes against success signals, capture lessons learned, and maintain a shared channel for issues and enhancements.
Success Reviews
- Success Review — Outcomes vs Success Signals
- Lessons Learned & Root Cause Workshop
- Regulatory Readiness & Audit Evidence Handoff
- Governance, Support & Enhancement Channel Setup
Issues & Enhancements
- Open the initial enhancement backlog items in the agreed intake tool and schedule the first prioritization session.
- Publish a Lessons Learned report containing RCA outputs, prioritized CAPAs, owners, and verification metrics.
- Update affected SOPs and training plans and schedule targeted retraining for roles where human factors contributed to incidents.
- Plan a small pilot test for each high‑priority CAPA and schedule follow-up verification sessions.
- Single‑sentence Future State & Audit Criteria
- Deliver a complete, audit‑ready evidence package or a clear list of outstanding evidence with owners and deadlines.
- Obtain quality organization agreement that package meets inspection readiness or set remediation path and timeline.
- Establish a process for responding to inspection questions and designate audit contacts.
- Provide the final audit package (electronic folder with index) and a one‑page audit summary to Quality for filing.
- List missing or supplemental artifacts with owners and deliverable dates for completion before any scheduled inspection.
- Schedule a mock inspection with defined scope and observers if Quality requests one.
- Governance Model Overview
- Create a shared collaboration channel with defined access and data handling rules for ongoing issues and enhancements.
- Agree on support SLAs and escalation paths to minimize downtime and ensure rapid remediation for identity incidents.
- Define an enhancement intake and prioritization workflow that maps to regulatory risk and operational benefit.
- Provision the agreed shared channel (tool, workspace) and invite the governance and operational teams with access rules.
- Publish the support SLA and escalation matrix to the channel and confirm acceptance from customer support/quality leads.
- Opening & Objectives
- Confirm whether the deployment meets the pre‑defined acceptance criteria for success signals.
- Quantify the operational and regulatory impact of results and identify any residual risk.
- Assign owners and timelines for any remediation or formal acceptance sign‑off.
- Deliver a validated metrics report with raw evidence links and a one‑line conclusion for each success signal.
- If gaps exist, produce a remediation plan with owners, milestones, and expected re‑validation criteria.
- Schedule the formal acceptance sign‑off meeting or confirm acceptance by documented email within 3 business days.
- Framing & Pre‑work Review
- Document root causes for deployment deviations and near‑misses with evidence and context.
- Produce a prioritized list of corrective and preventive actions (CAPAs) with owners and verification criteria.
- Ensure improvements explicitly map to improving identity reliability and audit readiness.
- Audit Package Review
- Shared Channel Definition & Access
- One‑sentence Current State
- Root Cause Analysis (facilitated)
- Traceability Walkthrough with Real Records
- Metric-by-Metric Verification
- Support Model & SLAs
- Operational Impact & Workarounds
- Acceptance Checks & Sign‑off Criteria
- Consequence Mapping
- Prioritization of Improvements
- Enhancement Intake & Prioritization Process
- Assign Owners, Timelines & Success Metrics
- Cadence & First Quarterly Review
- Validation & Customer Confirmation
- Contingency Evidence for Near‑Misses
- Decision & Next Steps